VIDEO: All-oral selinexor combination well-tolerated in multiple myeloma
Once weekly oral selinexor combined with pomalidomide and dexamethasone was well-tolerated in patients with heavily pretreated multiple myeloma, according to data from the multi-arm phase 1b/2 STOMP study presented at the virtual ASCO Annual Meeting.
When patients received the recommended phase 2 dose, the overall response rate was about 60% and one-third of patients achieved very good partial response, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.
“The reason why it’s interesting is because, as you can imagine, it’s an all-oral combination,” Gasparetto said. “So, for patient convenience, a lot of time we chose patients who need to travel [or] who don’t have a lot of social support to receive the weekly administration.”
Collapse
White D, et al. Abstract 8018. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).
Read more about